v3.25.2
Segment and Geographic Information - Segment Reporting (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Apr. 26, 2024
Apr. 25, 2025
Apr. 26, 2024
Apr. 28, 2023
Segment Reporting Information [Line Items]        
Net sales   $ 33,537 $ 32,364 $ 31,227
Cost of products sold, excluding amortization of intangible assets   11,632 11,216 10,719
Research and development expense   2,732 2,735 2,696
Selling, general, and administrative expense   10,849 10,736 10,415
Reportable segment operating profit   5,955 5,144 5,485
Other non-operating income, net   402 412 515
Amortization of intangible assets   (1,807) (1,693) (1,698)
Stock-based compensation   (429) (393) (355)
Restructuring and associated costs $ (300)      
Certain litigation charges, net   (317) (149) 30
Income before income taxes   5,628 4,837 5,364
Reportable segments        
Segment Reporting Information [Line Items]        
Net sales   33,489 32,142 30,731
Cost of products sold, excluding amortization of intangible assets   10,987 10,385 9,704
Research and development expense   2,478 2,452 2,323
Selling, general, and administrative expense   7,541 7,365 7,096
Other segment items   (36) (39) (57)
Reportable segment operating profit   12,518 11,979 11,664
Segment reconciling items        
Segment Reporting Information [Line Items]        
Corporate   (1,837) (1,784) (1,763)
Interest expense, net   (729) (719) (636)
Other non-operating income, net   402 412 515
Amortization of intangible assets   (1,807) (1,693) (1,698)
Stock-based compensation   (429) (393) (355)
Centralized distribution costs   (1,650) (1,609) (1,558)
Currency   (3) 68 465
Restructuring and associated costs   (303) (389) (647)
Acquisition and divestiture-related items   (124) (777) (345)
Certain litigation charges, net   (317) (149) 30
Medical device regulations   (52) (119) (150)
Other adjustments   (90)    
Commitments to the Medtronic Foundation and Medtronic LABS       (70)
Cardiovascular        
Segment Reporting Information [Line Items]        
Net sales   12,481 11,831 11,522
Cardiovascular | Reportable segments        
Segment Reporting Information [Line Items]        
Net sales   12,481 11,831 11,522
Cost of products sold, excluding amortization of intangible assets   3,967 3,731 3,562
Research and development expense   931 906 815
Selling, general, and administrative expense   2,824 2,748 2,653
Other segment items   (41) (28) (31)
Reportable segment operating profit   4,801 4,474 4,522
Neuroscience        
Segment Reporting Information [Line Items]        
Net sales   9,846 9,406 8,959
Neuroscience | Reportable segments        
Segment Reporting Information [Line Items]        
Net sales   9,846 9,406 8,959
Cost of products sold, excluding amortization of intangible assets   2,762 2,634 2,411
Research and development expense   542 556 573
Selling, general, and administrative expense   2,327 2,245 2,189
Other segment items   31 30 74
Reportable segment operating profit   4,183 3,940 3,712
Medical Surgical        
Segment Reporting Information [Line Items]        
Net sales   8,407 8,417 7,989
Medical Surgical | Reportable segments        
Segment Reporting Information [Line Items]        
Net sales   8,407 8,417 7,989
Cost of products sold, excluding amortization of intangible assets   3,142 3,057 2,859
Research and development expense   606 587 543
Selling, general, and administrative expense   1,600 1,594 1,549
Other segment items   18 9 (10)
Reportable segment operating profit   3,042 3,170 3,048
Diabetes        
Segment Reporting Information [Line Items]        
Net sales   2,755 2,488 2,262
Diabetes | Reportable segments        
Segment Reporting Information [Line Items]        
Net sales   2,755 2,488 2,262
Cost of products sold, excluding amortization of intangible assets   1,117 963 871
Research and development expense   400 402 392
Selling, general, and administrative expense   791 778 705
Other segment items   (43) (49) (90)
Reportable segment operating profit   491 394 383
Other Segment | Reportable segments        
Segment Reporting Information [Line Items]        
Net sales   137 221 495
Reportable segment operating profit   $ 49 $ 10 $ (89)